Reaction
Parvovirus Infection reporting signals
As of the last recalculation, Parvovirus Infection appears in 375 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 68.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 14 | 68.6 | 68.7 |
| Ganciclovir | 12 | 67.2 | 67.3 |
| Ganciclovir Sodium | 12 | 65.0 | 65.1 |
| Anakinra | 18 | 63.2 | 63.3 |
| Valganciclovir | 17 | 52.4 | 52.4 |
| Valganciclovir Hydrochloride | 17 | 52.4 | 52.4 |
| Valganciclovir Hydrochloride Powder, | 10 | 46.7 | 46.8 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 41.9 | 42.0 |
| Fludarabine Phosphate | 21 | 31.3 | 31.4 |
| Daptomycin | 4 | 24.3 | 24.3 |
| Ipilimumab | 14 | 18.7 | 18.7 |
| Acalabrutinib | 4 | 18.5 | 18.5 |
| Palivizumab | 3 | 10.9 | 10.9 |